Two Sigma Investments LP Grows Stock Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)

Two Sigma Investments LP boosted its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 71.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 306,272 shares of the company's stock after buying an additional 127,219 shares during the period. Two Sigma Investments LP owned approximately 0.36% of CRISPR Therapeutics worth $12,055,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also bought and sold shares of CRSP. Hedges Asset Management LLC boosted its holdings in CRISPR Therapeutics by 5.1% in the 4th quarter. Hedges Asset Management LLC now owns 24,350 shares of the company's stock valued at $958,000 after purchasing an additional 1,188 shares during the period. PFG Investments LLC boosted its holdings in CRISPR Therapeutics by 9.9% in the 4th quarter. PFG Investments LLC now owns 10,603 shares of the company's stock valued at $417,000 after purchasing an additional 952 shares during the period. KBC Group NV boosted its holdings in CRISPR Therapeutics by 2,047.4% in the 4th quarter. KBC Group NV now owns 60,514 shares of the company's stock valued at $2,382,000 after purchasing an additional 57,696 shares during the period. Perigon Wealth Management LLC boosted its holdings in CRISPR Therapeutics by 11.4% in the 4th quarter. Perigon Wealth Management LLC now owns 16,757 shares of the company's stock valued at $675,000 after purchasing an additional 1,717 shares during the period. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in CRISPR Therapeutics by 10.5% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 18,098 shares of the company's stock valued at $712,000 after purchasing an additional 1,717 shares during the period. 69.20% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other CRISPR Therapeutics news, COO Julianne Bruno sold 1,198 shares of the business's stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total value of $50,819.16. Following the transaction, the chief operating officer now owns 8,263 shares in the company, valued at approximately $350,516.46. The trade was a 12.66% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Samarth Kulkarni sold 9,973 shares of the business's stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total transaction of $423,054.66. Following the completion of the transaction, the chief executive officer now owns 180,890 shares in the company, valued at $7,673,353.80. The trade was a 5.23% decrease in their position. The disclosure for this sale can be found here. Insiders sold 14,021 shares of company stock valued at $594,771 over the last three months. Insiders own 4.10% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages have commented on CRSP. Chardan Capital cut their price target on shares of CRISPR Therapeutics from $84.00 to $82.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. Barclays cut their price target on shares of CRISPR Therapeutics from $56.00 to $42.00 and set an "equal weight" rating for the company in a report on Friday, May 9th. Cantor Fitzgerald reissued a "neutral" rating on shares of CRISPR Therapeutics in a report on Wednesday, February 19th. Citigroup dropped their price objective on shares of CRISPR Therapeutics from $89.00 to $82.00 and set a "buy" rating for the company in a report on Tuesday, February 18th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $65.00 price objective on shares of CRISPR Therapeutics in a report on Tuesday, May 20th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Hold" and an average price target of $71.75.

CRISPR Therapeutics Price Performance

CRISPR Therapeutics stock traded down $0.31 during mid-day trading on Thursday, hitting $36.91. The company's stock had a trading volume of 1,033,573 shares, compared to its average volume of 1,693,274. The stock has a market cap of $3.19 billion, a price-to-earnings ratio of -8.44 and a beta of 1.88. The business has a 50 day moving average price of $36.80 and a 200-day moving average price of $41.71. CRISPR Therapeutics AG has a 12 month low of $30.04 and a 12 month high of $67.88.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported ($1.58) earnings per share for the quarter, missing the consensus estimate of ($1.27) by ($0.31). CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. CRISPR Therapeutics's revenue was up 71.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($1.43) earnings per share. On average, equities research analysts expect that CRISPR Therapeutics AG will post -5.16 earnings per share for the current fiscal year.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.